MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Founder and CEO Justin Hanka recently joined the TechMediaWire Podcast to discuss the company's artificial intelligence-driven voice analysis technology, which is designed to detect drug and alcohol intoxication through noninvasive speech analysis. The interview highlighted the limitations of traditional testing methods and MindBio's commercial focus on regulated workplace environments such as mining, where the company believes its scalable detection platform could improve safety by expanding real-time intoxication screening capabilities.
MindBio is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
During the podcast, Hanka outlined how traditional methods, such as breathalyzers and blood tests, are often invasive, time-consuming, and limited in scope. In contrast, MindBio's voice analysis technology offers a noninvasive, scalable solution that can be deployed in real-time across various settings. The potential impact on workplace safety is significant, particularly in high-risk industries like mining, where impairment due to drugs or alcohol can lead to accidents and fatalities. By enabling continuous or on-demand screening, the technology could help employers identify intoxicated individuals before they engage in safety-sensitive tasks.
The implications extend beyond mining. The company's technology is also being targeted at aviation, construction, and law enforcement sectors, all of which require strict adherence to sobriety for safety. The ability to detect impairment quickly and noninvasively could reduce the burden on employers and enhance overall safety protocols.
For more information on MindBio Therapeutics, visit the company's newsroom at https://ibn.fm/MBQIF. To view the full press release, visit https://ibn.fm/SU3Ay.
